Are you Dr. Tetzlaff?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 47 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Michael Tetzlaff, MD is a board certified pathologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alaska, and Illinois. He is affiliated with University of California San Francisco Medical Center at Mount Zion.
Education & Training
University of Pennsylvania Health SystemFellowship, Dermatopathology, 2009 - 2010- University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 2005 - 2009
Baylor College of MedicineClass of 2005
Certifications & Licensure
CA State Medical License 2020 - 2026
IL State Medical License 2021 - 2026
TX State Medical License 2010 - 2025
AK State Medical License 2022 - 2024
PA State Medical License 2005 - 2010- American Board of Pathology Pathology - Anatomic
- American Board of Pathology Dermatopathology
Publications & Presentations
PubMed
- 22 citationsAmbiguous melanocytic tumors in a tertiary referral center: the contribution of fluorescence in situ hybridization (FISH) to conventional histopathologic and immunophe...Michael T. Tetzlaff, Wei Lien Wang, Tiffani L. Milless, Jonathan L. Curry, Carlos Torres-Cabala
The American Journal of Surgical Pathology. 2013-12-01 - 25 citationsToward a Molecular-Genetic Classification of Spitzoid Neoplasms.Michael T. Tetzlaff, Alexandre Reuben, Steven D. Billings, Victor G. Prieto, Jonathan L. Curry
Clinics in Laboratory Medicine. 2017-09-01 - 16 citationsImpact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms.Sarah Benton, Jeffrey Zhao, Bin Zhang, Armita Bahrami, Raymond L. Barnhill
The American Journal of Surgical Pathology. 2021-12-01
Press Mentions
Lichenoid Dermatitis with Mycosis Fungoides Features Linked to Checkpoint Inhibitor TherapyJuly 28th, 2019
Dual Neoadjuvant Checkpoint Blockade Feasible in MelanomaOctober 11th, 2018
Neoadjuvant Combination Checkpoint Blockade Trial Yields High Response Rates for Patients with High-Risk Stage Three MelanomaOctober 8th, 2018- Join now to see all
